



Epzicom® (abacavir/lamivudine) – First-Time Generic

- On September 29, 2016, Teva announced the [FDA approval](#) of an [AB-rated](#) generic version of ViiV Healthcare's [Epzicom \(abacavir/lamivudine\)](#) 600 mg/300 mg tablets.
 - Teva was awarded 180 days of market exclusivity.
 - In addition, Prasco has launched an authorized generic version of Epzicom.
- Epzicom is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
- Epzicom carries a boxed warning for hypersensitivity reactions, lactic acidosis and severe hepatomegaly, and exacerbations of hepatitis B.
- According to IMS Health, Epzicom had U.S. sales of approximately \$449 million for 12 months ending in July 2016.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.